CRIS Current Research Information System

BISELLI, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.644
EU - Europa 2.945
AS - Asia 1.711
AF - Africa 215
SA - Sud America 18
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 9.541
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.635
GB - Regno Unito 701
IT - Italia 548
CN - Cina 505
SE - Svezia 502
VN - Vietnam 495
SG - Singapore 397
DE - Germania 371
IN - India 170
IE - Irlanda 139
UA - Ucraina 126
CH - Svizzera 116
FR - Francia 105
RU - Federazione Russa 105
TG - Togo 100
JO - Giordania 80
ZA - Sudafrica 54
EE - Estonia 53
BG - Bulgaria 46
FI - Finlandia 42
CI - Costa d'Avorio 29
IR - Iran 22
NL - Olanda 22
BE - Belgio 20
NG - Nigeria 19
HR - Croazia 13
SC - Seychelles 11
CA - Canada 9
JP - Giappone 9
EC - Ecuador 8
ES - Italia 7
ID - Indonesia 7
AU - Australia 6
PL - Polonia 5
CL - Cile 4
DK - Danimarca 4
LB - Libano 4
RO - Romania 4
UZ - Uzbekistan 4
AT - Austria 3
BR - Brasile 3
CZ - Repubblica Ceca 3
GR - Grecia 3
MK - Macedonia 3
TH - Thailandia 3
BD - Bangladesh 2
EU - Europa 2
HK - Hong Kong 2
MM - Myanmar 2
MY - Malesia 2
PH - Filippine 2
PT - Portogallo 2
SA - Arabia Saudita 2
BO - Bolivia 1
FK - Isole Falkland (Malvinas) 1
IL - Israele 1
KR - Corea 1
LU - Lussemburgo 1
MA - Marocco 1
NO - Norvegia 1
PE - Perù 1
SN - Senegal 1
TR - Turchia 1
Totale 9.541
Salva come PNG Salva come JPEG
Città #
Southend 628
Fairfield 590
Chandler 510
Dong Ket 415
Ashburn 379
Singapore 344
Woodbridge 286
Houston 274
Seattle 258
Wilmington 223
Cambridge 208
Bologna 176
Santa Clara 173
Princeton 172
Ann Arbor 154
Dublin 138
Boardman 110
Bern 105
Lomé 100
Amman 80
Jacksonville 78
Redmond 70
Westminster 66
Padova 57
Berlin 55
Nanjing 51
Sofia 43
Shenyang 42
Helsinki 39
Jinan 37
Beijing 36
San Diego 36
Florence 32
New York 32
Saint Petersburg 31
Turin 31
Milan 30
Abidjan 29
Bremen 25
Nanchang 23
Hebei 22
Tianjin 21
Brussels 20
Abeokuta 19
Des Moines 18
Hangzhou 16
Medford 16
Changsha 15
Mülheim 15
Dearborn 14
Rome 14
Norwalk 13
Paris 13
Washington 13
Falls Church 12
Guangzhou 12
Jiaxing 12
Olalla 12
Shanghai 12
Mahé 11
London 10
Redwood City 10
Wuhan 10
Zhengzhou 10
Falkenstein 9
Fort Worth 9
Los Angeles 9
Munich 9
Ardabil 8
Ningbo 8
Phoenix 8
San Francisco 8
Tokyo 8
Jakarta 7
Lübeck 7
Amsterdam 6
Costa Mesa 6
Frankfurt Am Main 6
Guayaquil 6
Leawood 6
Mountain View 6
Saint Louis 6
Zanjan 6
Bühl 5
Hyderabad 5
Kuban 5
Napoli 5
Ottawa 5
Ancona 4
Andover 4
Catania 4
Chicago 4
Fremont 4
Haikou 4
Hefei 4
Las Vegas 4
Moscow 4
Sacramento 4
Taiyuan 4
Wuxi 4
Totale 6.717
Salva come PNG Salva come JPEG
Nome #
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 216
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 187
Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. 185
Albumin homodimers in patients with cirrhosis: clinical and prognostic relevance of a novel identified structural alteration of the molecule. 183
Allocation priority in non urgent liver transplantation: an overview of proposed scoring systems 180
A new prognostic model to predict drop-out from the waiting list in cirrhotic candidates for liver transplantation wirh MELD score <18. 171
Acquired intestinal lymphangiectasia successfully treated with a low fat and MCT-enriched diet in a patient with liver transplantation. 166
BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. 166
Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. 165
null 164
Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma 161
An in-depth psychosocial and biochemical evaluation in transplant recipients for alcoholic liver disease should be planned. 159
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 159
Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial 148
Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatments and outcome. 148
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. 146
Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen. 143
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma 143
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA. database 141
Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients 138
Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft 138
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. 138
Monofocal hepatocellular carcinoma: How much does size matter? 138
Alcoholic liver disease: pathophisiological aspects and risk factors. A review. 136
Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis 135
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 133
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 132
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 131
Metabolic disorders across hepatocellular carcinoma in Italy 128
Chronic prostatitis/pelvic pain syndrome: MRI findings and clinical correlations. 126
Liver transplantation for patients with alcoholic liver disease: an open question 125
Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. 123
High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing Lamivudine resistance. 122
Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin 122
Authors’ reply: Comment to “Liver transplantation for patients with alcoholic liver disease: An open question” 122
Posttranscriptional changes of serum albumin: clinical and prognostic meaning in hospitalized patients with cirrhosis. 120
New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: A new diagnostic algorithm 119
In vitro effect of indomethacin and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C 118
Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma 118
null 117
Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case controlled study 116
Trattamento dell’epatopatia alcolica 115
Prognostic Role of Bacterial and Fungal Infections in Patients with Liver Cirrhosis with and without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study 114
What is the best fruit juice to use as a negative oral contrast agent in magnetic resonance cholangiopancreatography? 112
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 112
Optimization of pineapple juice amount used as a negative oral contrast agent in magnetic resonance cholangiopancreatography 112
The MELD score in patients awaiting liver transplant: strengths and weaknesses. 111
QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. 111
Years of life that could be saved from prevention of hepatocellular carcinoma. 111
Two years Mycophenolate Mofetil plus low dose calcineurin inhibitor for renal dysfunction after liver transplantation. 111
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. 111
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C. 110
High incidence of allograft dysfunction in liver transplant patients treated with PEG-Interferon alfa-2b and Ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? 110
Pattern of macrovascular invasion in hepatocellular carcinoma 108
Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study 104
Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: which is the winner? 104
GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) ADMINISTRATION IN CIRRHOTIC PATIENTS: A PHASE II STUDY EVALUATING TOLERABILITY PROFILE AND MOBILIZATION OF HAEMATOPOIETIC STEM CELLS (HSCS). 103
Hepatic artery stenosis in liver transplanted patients treated with pegylated Interferon alpha-2b and Ribavirin 95
null 95
Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? 94
OUTCOME OF LIVER TRANSPLANT FOR ALCOHOLIC LIVER DISEASE. 94
PEGYLATED INTERFERON PLUS RIBAVIRIN FOR THE TREATMENT OF RECURRENT HCV INFECTION AFTER LIVER TRANSPLANTATION 92
Development and validation of a scoring system that includes corrected QT interval for risk analysis of patients with cirrhosis and gastrointestinal bleeding 91
Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis 89
null 83
New MRI series for kidney evaluation: Saving time and money 83
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 81
Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy. 77
Sustained and focused HBV-nucleocapsid-specific T cell immunity in liver transplant recipients compared to individuals with chronic and self-limited HBV infection. 76
The evolutionary scenario of hepatocellular carcinoma in Italy: an update. 74
null 72
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. 71
OUTCOME OF LIVER TRANSPLANT FOR ALCOHOLIC LIVER DISEASE 70
Hepatocellular carcinoma surveillance: an open question 64
The changing scenario of hepatocellular carcinoma in Italy: an update 58
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 51
Liver injury with novel oral anticoagulants: Assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system 49
Increased survival after sustained virological response in liver transplanted patients with HCV recurrence: taking-up a challenge for the hepatologist. 48
A modified Child-Turcotte-Pugh (CTP) for selection of patients affected by cirrhosis candidates for liver transplantation (LT) with low model for end-stage liver disease score (MELD) 48
Increased survival after sustained virological response in liver transplanted patients with HCV recurrence: taking-up a challenge for the hepatologist. 47
A modified Child-Turcotte-Pugh (CTP) for selection of candidates to liver transplantation (LT) with low model for end-stage liver disease score (MELD). 45
Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents? 43
Reply to “Re: Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma—A Propensity Analysis” 40
Seven score systems to evaluate candidates to orthotopic liver transplantation: which is the winner? 36
Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival 35
Natremia and Child-Turcotte-Pugh (CTP) may improve the selection of candidates for liver transplantation (LT) with lower model for end-stage liver disease score (MELD). 33
Natremia and Child-Turcotte-Pugh (CTP) score may improve the selection of candidates for liver transplantation (LT) with lower model for end-stage liver disease score (MELD) 31
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 30
Prognosis of untreated hepatocellular carcinoma. 22
The Gastropack Access System as a Model to Access Gastroenterology Services for Gastroscopy Appropriateness in Patients with Upper Gastrointestinal Symptoms: A Comparison with the Open Access System 21
Magnetic Resonance Enterography Reinvented: Exploring the Potential of a New Natural Beverage as an Alternative to Polyethylene Glycol Solution 17
Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib 16
Totale 9.756
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.598
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.598
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.378 0 0 0 0 0 208 267 280 301 154 71 97
2020/20211.367 218 95 20 61 11 60 35 51 110 72 63 571
2021/20221.849 133 83 81 153 138 101 45 145 66 145 491 268
2022/20232.136 194 338 99 286 113 179 79 105 360 66 160 157
2023/2024621 64 87 45 50 48 131 21 61 28 31 35 20
2024/20251.089 80 286 179 179 277 88 0 0 0 0 0 0
Totale 9.756